Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors

Activation of immune checkpoint pathways and limited T- cell infiltration result in immunological escape of tumors. Although immune checkpoint inhibitors are currently approved for several types of cancers, the response rate is often limited by the lack of tumor specific T-cells within the malignant...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncoimmunology
Hlavní autoři: Feola, S., Capasso, C., Fusciello, M., Martins, B., Tähtinen, S., Medeot, M., Carpi, S., Frascaro, F., Ylosmäki, E., Peltonen, K., Pastore, L., Cerullo, V.
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2018
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6136871/
https://ncbi.nlm.nih.gov/pubmed/30221051
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1457596
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky